You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Bulk Pharmaceutical API Sources for CLIDINIUM BROMIDE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for CLIDINIUM BROMIDE

Vendor Vendor Homepage Vendor Sku API Url
NovoSeek ⤷  Start Trial 19004 ⤷  Start Trial
ISpharm ⤷  Start Trial I06-0406 ⤷  Start Trial
MP Biomedicals ⤷  Start Trial 154994 ⤷  Start Trial
MolPort ⤷  Start Trial MolPort-003-666-147 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Clidinium Bromide

Last updated: August 15, 2025

Introduction

Clidinium bromide is a quaternary ammonium anticholinergic agent primarily used to manage gastrointestinal disorders such as peptic ulcers, functional dyspepsia, and irritable bowel syndrome (IBS). Its therapeutic efficacy hinges on its purity and quality, which depend heavily on reliable bulk API sourcing. Given the increased regulation and quality standards in pharmaceuticals, sourcing high-quality clidinium bromide API from reputable manufacturers is crucial for pharmaceutical companies, formulators, and distributors.

This article examines the global landscape of bulk API sources for clidinium bromide, analyzing manufacturing regions, key suppliers, and the considerations involved in selecting a reliable supply chain.

Overview of Clidinium Bromide API

Clidinium bromide, chemically known as 1-[(2-chlorophenyl)(cyclopentyl)acetyl]-4-methylpiperazine bromide, is a synthetic, highly potent antimuscarinic agent demonstrating anticholinergic activity. Its quality and consistency are vital for drug safety and efficacy, which starts from the quality of the API supplied.

The API supply market is characterized by a mixture of large-scale manufacturers, generic producers, and contract manufacturing organizations (CMOs). Regulatory compliance, manufacturing capacity, and the quality assurance frameworks are central to choosing an API source.


Global API Manufacturing Regions for Clidinium Bromide

1. China

China remains a dominant hub for bulk API production, including compounds like clidinium bromide. Chinese API manufacturers have significantly expanded their capacities over the last decade, leveraging advanced chemical synthesis technologies and cost efficiencies. Major Chinese API producers are well-regarded for their large-scale manufacturing capabilities, competitive pricing, and extensive distribution networks.

Notable Chinese API Manufacturers:

  • Shenzhen Salubris Pharmaceuticals Co., Ltd. – Known for manufacturing various gastrointestinal APIs, including anticholinergics.

  • Jiangsu Hengrui Medicine Co., Ltd. – A comprehensive pharmaceutical company with API production facilities adhering to GMP standards.

  • Harbin Pharmaceutical Group Co., Ltd. (HPGC) – Offers a broad portfolio, including specialty APIs.

2. India

India’s pharmaceutical industry is a global leader in API manufacturing, particularly for generic drugs and specialty APIs like clidinium bromide. Indian API producers benefit from stringent regulatory standards, proven quality assurance systems, and a robust export market.

Leading Indian API Suppliers:

  • Glenmark Pharmaceuticals – Operates large-scale manufacturing units for gastrointestinal APIs.

  • Aurobindo Pharma Ltd. – A key player in producing high-quality APIs, including anticholinergic compounds.

  • Hetero Drugs Ltd. – Known for adhering to international standards and offering reliable sourcing options.

3. Europe and North America

While manufacturing capacity for clidinium bromide itself is limited in Europe and North America, some specialized contract manufacturers and pharmaceutical conglomerates produce high-purity APIs meeting rigorous regulatory standards such as FDA and EMA.

  • EU-based CMOs and API developers – Focus on high-quality standards, compliance, and supply reliability for niche pharmaceutical APIs.

  • U.S. contract manufacturers – Usually supply for clinical trials or specialized formulations, though less predominant for bulk production compared to Asian manufacturers.

4. Other Regions

  • Korea and Japan – Known for technological advancements in pharmaceutical manufacturing, though production of clidinium bromide is less prevalent here.

Key Criteria for Selecting API Suppliers

Choosing the right bulk API supplier involves evaluating several critical factors:

Quality and Compliance Standards

  • GMP Certification: Ensures compliance with Good Manufacturing Practices, critical for pharmaceutical APIs.
  • Regulatory Approval: Suppliers should have approvals from authorities like the FDA, EMA, or other relevant agencies.
  • Third-party Testing: Laboratories conducting rigorous quality testing for impurity profiles, potency, moisture content, and endotoxins.

Manufacturing Capacity and Lead Times

  • Capacity to Meet Demand: Reliable suppliers should demonstrate consistent production capabilities, especially for bulk orders.
  • Lead Time & Delivery Reliability: Quick turnaround times help in maintaining supply chain stability.

Pricing and Contract Terms

  • Competitive pricing is essential, though it should not compromise quality.
  • Clear contractual terms regarding batch consistency, intellectual property rights, and liability.

Reputation and Track Record

  • Reviews from existing clients and market presence.
  • Proven compliance with international standards and past audits.

supply chain transparency and traceability

  • Traceable sourcing of raw materials.
  • Detailed documentation and quality certificates.

Key Global API Suppliers for Clidinium Bromide

Manufacturer Region Certification & Compliance Notable Features
Jiangsu Hengrui China GMP, ISO Large-scale, cost-effective
Zhejiang Haizhou Pharmaceutical China GMP, cGMP Focus on quality control
Aurobindo Pharma India WHO GMP, USFDA Extensive product portfolio
Hetero Drugs India USFDA, EUGMP Reliable supply chain
CAMBREX USA cGMP, FDA-approved High purity standards
WuXi AppTec China GMP, CLIA Contract manufacturing & API

Note: Confirm current certifications and approvals directly with manufacturers.


Regulatory and Logistic Considerations

Transparency in the sourcing process, adherence to regulatory standards, and logistical efficiencies are pivotal in API sourcing. Manufacturers compliant with international standards facilitate streamlined regulatory approvals and reduce compliance risks.

Logistics considerations include:

  • Export Restrictions: Some regions impose restrictions on the export of pharmaceuticals and APIs.
  • Shipping Conditions: APIs often require temperature-controlled environments to maintain stability.
  • Lead Times & Inventory Management: Maintain buffer stock levels to avoid shortages caused by supply chain disruptions.

Conclusion

Secure sourcing of bulk clidinium bromide API hinges on evaluating manufacturing quality, compliance standards, and supply chain reliability. China and India remain leading regions due to their manufacturing scale and cost advantages, but European and North American suppliers provide high-quality, regulatory-compliant options for specialized needs.

Establishing partnerships with reputable API manufacturers is vital for ensuring product efficacy, regulatory compliance, and supply chain resilience. Due diligence, ongoing quality audits, and transparent documentation are indispensable components of a robust sourcing strategy.


Key Takeaways

  • Prioritize regulatory compliance: GMP certification and approval from authorities like the FDA or EMA are non-negotiable for quality assurance.
  • Assess manufacturing capacity: Ensure suppliers can meet current and future demand with reliable lead times.
  • Evaluate supplier reputation: Choose manufacturers with proven track records and robust quality management systems.
  • Balance cost and quality: While cost is a factor, it should not override critical quality standards, especially for active pharmaceutical ingredients.
  • Consider logistical factors: Shipping conditions, documentation, and supply chain transparency safeguard against unforeseen disruptions.

FAQs

1. Is Chinese API production for clidinium bromide considered reliable?
Yes. Many Chinese API manufacturers possess GMP certification and meet international regulatory standards, making them reliable sources for high-quality clidinium bromide API when properly vetted.

2. What regulatory considerations should be made when sourcing APIs internationally?
Manufacturers should hold certifications such as GMP, ISO, and approvals from agencies like the FDA or EMA. Additionally, import-export regulations, customs, and language barriers should be considered for seamless procurement.

3. How can companies verify the quality of external API suppliers?
Through audits, reviewing third-party testing reports, and examining certifications. Regular QC testing of received batches further ensures API integrity.

4. Are there any risks associated with sourcing APIs from low-cost regions?
Potential risks include inconsistent quality, regulatory non-compliance, and supply chain disruptions. Due diligence and supplier audits mitigate these risks.

5. Can contract manufacturing organizations (CMOs) provide custom formulations of clidinium bromide?
Yes. CMOs can produce APIs as well as custom formulations, provided they have the appropriate technology, capacity, and regulatory approval.


Sources
[1] U.S. Food and Drug Administration. “Guidance for Industry: Chemistry, Manufacturing, and Controls Changes to an Approved NDA or ANDA” - FDA, 2021.
[2] European Medicines Agency. “Guideline on good manufacturing practice and quality control of medicinal products.” EMA, 2020.
[3] GlobalData Healthcare. “API manufacturing landscape analysis,” 2022.
[4] MarketWatch. “Top API producers worldwide,” 2023.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.